Skip to main content
Premium Trial:

Request an Annual Quote

Orchid Biosciences Seeks to Change Name to Orchid Cellmark

NEW YORK, April 14 (GenomeWeb News) - Orchid Biosciences is seeking stockholder approval to change its name to Orchid Cellmark to reflect the company's positioning as a provider of DNA identity testing services, the firm said yesterday.

Shareholders will consider the name change at the Princeton, NJ-based company's annual stockholders meeting on June 8.

The new name would reflect the Cellmark DNA testing services unit, AstraZeneca's UK genetic testing subsidiary that Orchid acquired in 2001.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.